Evidence map›Paper›PMID 32887638›Full record

ArticleJournal of translational medicine2020

Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report).

Irene Dell'Anno, Elisa Barone, Luciano Mutti, Doris M Rassl, Stefan J Marciniak, Roberto Silvestri, Stefano Landi, Federica Gemignani

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Frontiers in genetics · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Irene Dell'AnnoDepartment of Biology, University of Pisa, Pisa, Toscana, Italy.
Elisa BaroneDepartment of Biology, University of Pisa, Pisa, Toscana, Italy.
Luciano MuttiSbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.
Doris M RasslRoyal Papworth Hospital NHS Trust, Papworth Road, Cambridge Biomedical Campus, Cambridge, B2 0AY, UK.
Stefan J MarciniakCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
Roberto SilvestriDepartment of Biology, University of Pisa, Pisa, Toscana, Italy.
Stefano LandiDepartment of Biology, University of Pisa, Pisa, Toscana, Italy. stefano.landi@unipi.it.
Federica GemignaniDepartment of Biology, University of Pisa, Pisa, Toscana, Italy.
University of Pisa · ITPapworth Hospital · GBTemple University · USUniversity of Cambridge · GB

Funding

Medical Research Council G0601840Medical Research Council G1002610Medical Research Council MR/R009120/1
6 · The paper itself

Abstract

backgroundMalignant pleural mesothelioma (MPM) is an aggressive neoplasm of the pleura, mainly related to asbestos exposure. As in other solid tumors, malignant cells exhibit high glucose uptake and glycolytic rates with increased lactic acid efflux into the interstitial space. Lactate transport into and out of cells, crucial to maintaining intracellular pH homeostasis and glycolysis, is carried out by monocarboxylate transporters (MCTs) and the chaperone basigin (CD147). We set out to examine the clinical significance of basigin, MCT1 and MCT4 in the context of MPM and to evaluate their expression in relation to the evolution of the disease.

methodsWe used immunohistochemistry to measure the expression of basigin, MCT1 and MCT4 in a cohort of 135 individuals with MPM compared to a series of 15 non-MPM pleura specimens. Moreover, by Kaplan-Meier and Cox analyses we evaluated whether an expression over the average of these markers could be associated with the patients' overall survival (OS).

resultsWe detected positive staining of basigin, MCT1, and MCT4 in most MPM specimens. In particular, MCT4 was always positive in malignant tissues but undetectable in the 4 normal pleural specimens incorporated within the tissue microarray. This was confirmed in the additional series of 15 normal pleural samples. Moreover, MCT4 expression was significantly associated with reduced OS.

conclusionIn this study, the tissue expression of basigin did not prove to be exploitable as a diagnostic or prognostic marker for MPM patients. The expression of MCT1 was not informative either, being tightly correlated with that of basigin. However, the expression of MCT4 showed promise as a diagnostic/therapeutic and prognostic biomarker.

Indexed as

Mesothelioma, MalignantSymportersBasiginHumansMonocarboxylic Acid TransportersMuscle ProteinsPrognosisBasiginMonocarboxylic Acid TransportersMuscle ProteinsSLC16A4 protein, humanSymportersBasigin (CD147)Immunohistochemistry (IHC)Malignant pleural mesothelioma (MPM)MCT1MCT4Tissue microarray (TMA)

Identifiers

PMID32887638
PMCPMC7650278
OpenAlexW3083392614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.